论文部分内容阅读
目的探讨奥扎格雷与依达拉奉联合治疗进展性脑梗死的疗效。方法选取2010年2月-2012年2月我院确诊的87例进展型脑梗死住院患者,按观察组47例和对照组40例划分,两组均给予常规治疗,观察组给予奥扎格雷与依达拉奉联合治疗,对照组仅给予奥扎格雷钠治疗,持续14d。对比两组NIHSS神经功能缺损评分、日常生活能力(ADL)评分及临床疗效。结果治疗14d后,观察组临床总有效率及NIHSS、ADL评分均明显优于对照组,P<0.05,差异有统计学意义。未见明显不良反应。结论应用奥扎格雷钠联合依达拉奉治疗能明显改善进展性脑梗死患者神经功能缺损症状,优于奥扎格雷钠单药治疗,毒副作用少,值得进一步观察及探讨。
Objective To investigate the efficacy of ozagrel combined with edaravone in the treatment of patients with progressive cerebral infarction. Methods Totally 87 inpatients with advanced cerebral infarction diagnosed in our hospital from February 2010 to February 2012 were divided into observation group (n = 47) and control group (n = 40), and the two groups were given routine treatment. The observation group was given ozagrel and Edaravone combined treatment, the control group was given only ozagrel sodium treatment, sustained 14d. The NIHSS neurological deficit scores, ADL scores and clinical outcomes were compared between the two groups. Results After treatment for 14 days, the clinical total effective rate and the NIHSS and ADL scores in the observation group were significantly better than those in the control group, P <0.05, the difference was statistically significant. No obvious adverse reactions. Conclusion Ozagrel combined with edaravone can significantly improve the symptoms of neurological deficits in patients with progressive cerebral infarction. Ozagrel sodium is superior to ozagrel monotherapy in the treatment of patients with fewer toxic side effects. It is worth further observation and discussion.